Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ENLV 
Enlivex Therapeutics Ltd (ENLV)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/18/2025: ENLV (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $10
1 Year Target Price $10
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -56.61% | Avg. Invested days 41 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/18/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 25.05M USD | Price to earnings Ratio - | 1Y Target Price 10 |
Price to earnings Ratio - | 1Y Target Price 10 | ||
Volume (30-day avg) 2 | Beta 0.83 | 52 Weeks Range 0.81 - 2.10 | Updated Date 09/17/2025 |
52 Weeks Range 0.81 - 2.10 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.57 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -34.82% | Return on Equity (TTM) -55.02% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 6739965 | Price to Sales(TTM) - |
Enterprise Value 6739965 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -1.49 | Shares Outstanding 23858301 | Shares Floating 21346022 |
Shares Outstanding 23858301 | Shares Floating 21346022 | ||
Percent Insiders 4.61 | Percent Institutions 10.91 |
Upturn AI SWOT
Enlivex Therapeutics Ltd
Company Overview
History and Background
Enlivex Therapeutics Ltd. is a clinical-stage immunotherapy company developing Allocetra, an off-the-shelf cell therapy designed to reprogram immune cells in life-threatening conditions. Founded in 2005, it focuses on harnessing the body's natural mechanisms for homeostasis.
Core Business Areas
- Immunotherapy Development: Develops and commercializes Allocetra for treating conditions like sepsis and cytokine storm associated with COVID-19 and other diseases.
Leadership and Structure
Dr. Oren Hershkovitz serves as CEO. The company has a board of directors and operates with departments dedicated to research, development, clinical trials, and business development.
Top Products and Market Share
Key Offerings
- Allocetra: An off-the-shelf cell therapy aimed at reprogramming immune cells to restore homeostasis in severe conditions like sepsis and cytokine storm. Market share data is not publicly available due to its clinical stage status. Competitors in treating sepsis and cytokine storm include companies developing monoclonal antibodies and other immunomodulatory therapies, such as Cytokinetics (CYTK) and InflaRx (IFRX).
Market Dynamics
Industry Overview
The immunotherapy market is rapidly growing, driven by advancements in cell therapy and gene editing. There is a significant unmet need for effective treatments for sepsis and cytokine storm.
Positioning
Enlivex is positioned as an innovator in cell therapy, focusing on restoring immune homeostasis rather than suppressing the immune system. This approach differentiates it from many competitors.
Total Addressable Market (TAM)
The TAM for sepsis and cytokine storm treatments is estimated to be in the billions of dollars. Enlivex aims to capture a significant share of this market with Allocetra, if approved. Estimates vary significantly based on the success of clinical trials and market penetration.
Upturn SWOT Analysis
Strengths
- Novel approach to immune modulation
- Potential for broad application in various inflammatory conditions
- Experienced management team
- Positive initial clinical trial results
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Reliance on a single product candidate (Allocetra)
- Regulatory hurdles and potential delays in approval
- Manufacturing complexities associated with cell therapies
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
- Securing regulatory approvals in key markets
- Advancements in manufacturing technologies
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Changes in regulatory landscape
- Economic downturn affecting investment in biotechnology
Competitors and Market Share
Key Competitors
- Cytokinetics (CYTK)
- InflaRx (IFRX)
- Numerous companies developing therapies for sepsis and cytokine storm
Competitive Landscape
Enlivex's competitive advantage lies in its novel approach to immune modulation. However, it faces challenges from larger companies with more resources and established market presence.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by progress in clinical trials and expansion of the company's intellectual property portfolio.
Future Projections: Future growth is contingent on successful clinical trials and regulatory approvals for Allocetra. Analyst estimates vary widely due to the inherent risks in drug development.
Recent Initiatives: Recent initiatives include enrolling patients in ongoing clinical trials and exploring potential partnerships.
Summary
Enlivex Therapeutics is a clinical-stage company with a novel approach to immune modulation through its Allocetra therapy. Its strengths lie in its unique technology and positive initial trial results, but it faces challenges related to funding, regulatory hurdles, and competition. Successful clinical trials and strategic partnerships are crucial for future growth. The company's success relies heavily on the clinical development and regulatory approval of Allocetra.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Press Releases
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data is estimated.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Enlivex Therapeutics Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 1995-12-12 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.enlivex.com |
Full time employees - | Website https://www.enlivex.com | ||
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee osteoarthritis. The company also develops 0189-22-KMC, which is in phase I/II clinical trial to treat end-stage knee osteoarthritis; 0006-24-KMC, which is in phase I/II clinical trial for the treatment of Basal thumb osteoarthritis; and ENX-CL-06-001 to treat Psoriatic arthritis and is in phase I/II clinical trial. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Ness Ziona, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.